Comparison of acebutolol with propranolol, quinidine, and placebo: Results of three multicenter arrhythmia trials
1985; Elsevier BV; Volume: 109; Issue: 5 Linguagem: Inglês
10.1016/0002-8703(85)90709-4
ISSN1097-6744
Autores Tópico(s)Cardiac pacing and defibrillation studies
ResumoAcebutolol was compared to placebo, propranolol, and quinidine for the suppression of chronic ventricular arrhythmia in three double-blind, randomized crossover studies. Patients averaged ≥ 10 to 30 premature ventricular contractions (PVCs) per hour in the baseline periods. Compared to baseline in all three studies, acebutolol significantly (p < 0.002 to p < 0.001) reduced mean total PVCs and complex PVCs. In all measurements, acebutolol was superior to placebo (p < 0.02 to p < 0.001) and comparable to propranolol and quinidine. During acebutolol treatment, 39% of the patients had reductions of ≥ 75% in mean hourly PVC frequency compared to 23% during placebo treatment (p = 0.02). Similar numbers of patients had ≥ 75% reductions during acebutolol treatment in comparison with propranolol and quinidine. Acebutolol was better tolerated than quinidine and produced an antiarrhythmic effect equivalent to that of propranolol, with a significantly (p < 0.01) lesser decrease in resting heart rate. The antiarrhythmic activity of acebutolol, its ancillary pharmacologic properties, and its tolerance by a diverse group of patients make acebutolol a significant tool for the clinician in the management of chronic arrhythmia.
Referência(s)